



## **Adverum Biotechnologies to Participate in Piper Jaffray's 31st Annual Healthcare Conference**

November 20, 2019

MENLO PARK, Calif., Nov. 20, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that the company will present at Piper Jaffray's 31<sup>st</sup> Annual Healthcare Conference on Wednesday, December 4, 2019 at 11:00 am EST.

A live audio webcast will be accessible under Events and Presentations in the Investors section of the company's website. The archived audio webcast will be available on the Adverum website following the presentation for 30 days.

### **About Adverum Biotechnologies, Inc.**

Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration. For more information, please visit [www.adverum.com](http://www.adverum.com).

### **Investor and Media Inquiries:**

Investors:

Myesha Lacy

Adverum Biotechnologies

Vice President, Investor Relations and Corporate Communications

[mlacy@adverum.com](mailto:mlacy@adverum.com)

1-650-304-3892

Media:

Cherilyn Cecchini, M.D.

Account Supervisor

[ccecchini@lifescipublicrelations.com](mailto:ccecchini@lifescipublicrelations.com)

1-646-876-5196

 [ADVERUM\\_ID\\_RGB  
200x49.jpg](#)

Source: Adverum Biotechnologies, Inc.